Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 88,779,352
  • Shares Outstanding, K 2,531,490
  • Annual Sales, $ 23,002 M
  • Annual Income, $ 3,499 M
  • 36-Month Beta 0.81
  • Price/Sales 3.89
  • Price/Cash Flow 11.45
  • Price/Book 6.06

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.90 +2.57%
on 06/12/17
35.60 -2.33%
on 06/22/17
+0.92 (+2.72%)
since 05/26/17
3-Month
29.63 +17.35%
on 04/21/17
35.60 -2.33%
on 06/22/17
+2.97 (+9.34%)
since 03/27/17
52-Week
25.55 +36.09%
on 12/07/16
35.60 -2.33%
on 06/22/17
+6.82 (+24.40%)
since 06/27/16

Most Recent Stories

More News
Minerva On Track to Initiate Phase III Schizophrenia Study

Minerva Neurosciences, Inc. (NERV) announced that it is on track to begin phase III studies on its key schizophrenia pipeline candidate MIN-101 in the second half of this year, as planned.

AZN : 34.77 (-1.08%)
ACAD : 28.87 (-0.48%)
ALKS : 57.92 (-0.65%)
NERV : 9.20 (-1.08%)
Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion

Novo Nordisk A/S (NVO) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 17-2 in favor of Victoza that the drug provides substantial evidence of cardiovascular risk...

AZN : 34.77 (-1.08%)
NVO : 43.84 (-1.24%)
MRK : 65.87 (-0.08%)
LLY : 83.52 (-0.90%)
5 Reasons Why You Should Invest in AstraZeneca (AZN) in 2017

London-based pharma giant, AstraZeneca plc (AZN) has a strong product portfolio and is one of the key players in the global cardiovascular market.

AZN : 34.77 (-1.08%)
LLY : 83.52 (-0.90%)
AGN : 248.57 (-0.14%)
NKTR : 19.64 (-0.51%)
Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study

Clovis Oncology, Inc. (CLVS) shares soared nearly 50% on Monday after it announced positive top-line results from a pivotal late-stage maintenance study on its newly launched ovarian cancer drug, Rubraca....

AZN : 34.77 (-1.08%)
CLVS : 92.89 (-1.66%)
TSRO : 147.52 (+0.55%)
RHHBY : 32.6700 (+0.62%)
4 Buy-Ranked Large Cap Pharma Stocks to Add to Your Portfolio

The Zacks-categorized Large Cap Pharmaceuticals industry is among the top 21% of the 256 Zacks-ranked industries -- here is a look at 4 top-ranked stocks from this sector.

BAYRY : 137.2915 (+0.43%)
AZN : 34.77 (-1.08%)
HLUYY : 55.9700 (-0.37%)
SNY : 49.42 (-0.34%)
Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why

Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.

AZN : 34.77 (-1.08%)
AMGN : 173.55 (-0.07%)
BIIB : 277.26 (-0.91%)
NKTR : 19.64 (-0.51%)
Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year

Shares of Clovis Oncology, Inc. (CLVS) continue to witness an upside. The uptrend started in the third quarter of 2016.

AZN : 34.77 (-1.08%)
CLVS : 92.89 (-1.66%)
TSRO : 147.52 (+0.55%)
RHHBY : 32.6700 (+0.62%)
Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused

Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.

AZN : 34.77 (-1.08%)
JNJ : 135.84 (-0.37%)
MRK : 65.87 (-0.08%)
LLY : 83.52 (-0.90%)
SHPG : 173.68 (+0.17%)
PFE : 33.87 (-0.50%)
BMY : 56.38 (-0.95%)
Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug

Pfizer, Inc. (PFE) announced a deal to buy exclusive EU commercialization rights to an anti-fungal treatment, Cresemba from Swiss pharma company, Basilea Pharmaceutica Ltd.

BAYRY : 137.2915 (+0.43%)
AZN : 34.77 (-1.08%)
PFE : 33.87 (-0.50%)
SNY : 49.42 (-0.34%)
J&J's Invokana Lowers Heart Issues, Raises Amputation Risk

Johnson & Johnson (JNJ) announced data from a large CANVAS outcomes program, which demonstrated that its type II diabetes drug Invokana (canagliflozin) was successful in reducing the risks of heart attacks...

AZN : 34.77 (-1.08%)
JNJ : 135.84 (-0.37%)
MRK : 65.87 (-0.08%)
LLY : 83.52 (-0.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Support & Resistance

2nd Resistance Point 35.50
1st Resistance Point 35.33
Last Price 34.77
1st Support Level 34.98
2nd Support Level 34.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.